Borreani C, Alfieri S, Infante G, et al. - In patients with hormone receptor-positive (HR+) breast cancer (BC) undergoing aromatase inhibitor (AIs) therapy, researchers sought to determine the profiles of psychological symptoms and quality of life (QoL). Questionnaires were administered at AI initiation (t0), 3 months after AI initiation (t1), and 6 months after AI initiation (t2). Among the 43 women enrolled in the study (t0), 37 completed the t1 evaluation and 29 the t2 evaluation. Patients exhibited a progressive decline in FACT-G and FACT-ES scores over time, specifically in the Physical, Emotional, and Endocrine subscales, and an increase in the SOM (somatization) subscale of the SCL-90-R. Four clusters related to different psychological symptoms and QoL evolution were identified over time. BMI levels were significantly higher in patients belonging to the cluster characterized by worsening symptoms and QoL over time were different than that of others in their Emotional subscale of the FACT-B and the Global Score, obsessive-compulsive, depression, anxiety, and sleep disorder dimensions of the SCL-90-R . The predictors for the “worst” cluster were three items from the SCL-90-R and two items from FACT Emotional Well-Being subscale.